Shadi Tabibian: A New Era in von Willebrand Disease Treatment
Shadi Tabibian, Deputy of research at Blood Diseases Research Centers in Iran University of Medical Sciences, shared a post on LinkedIn:
“A New Era in von Willebrand Disease Treatment
For decades, the management of von Willebrand disease has relied mainly on von Willebrand factor concentrates,desmopressin,antifibrinolytic agents, and hormonal therapies.
Although these treatments remain effective for many patients, important unmet needs persist, including treatment burden, variable clinical response, limited prophylactic options, and reduced quality of life.
A new generation of therapeutic strategies is now emerging.
These approaches include:
- Antibodies designed to increase endogenous VWF and factor VIII levels
- Novel agents for type 2B VWD-associated thrombocytopenia
- FVIII-mimetic and rebalancing therapies
- Engineered factor VIII molecules with prolonged half-life
- Platelet-inspired synthetic nanoparticles
- Long-acting antifibrinolytic strategies using siRNA
- Gene therapy, allele-selective silencing, and CRISPR-based gene editing
The most important shift is the movement away from a one-size-fits-all model toward phenotype-directed and personalized treatment.
Not every therapy will be appropriate for every subtype of VWD. Future success will depend on matching the mechanism of treatment to the patient’s VWD type, bleeding phenotype, clinical needs, and individual risk profile.
These innovations may ultimately reduce treatment burden, expand prophylactic options, and improve the quality of life of people living with VWD.”

Other posts featuring Shadi Tabibian on Hemostasis Today.
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome
-
Nov 17, 2026, 13:37Abdlemewla Ibrahim: Prasugrel vs Ticagrelor in ACS Patients Undergoing PCI
-
Nov 17, 2026, 13:30Stacy E. Croteau: Oral and Dental Care in Pediatric Patients With Bleeding Disorders
-
Nov 17, 2026, 13:19Efe Saglam: Cannabis Use and Cardiac Conduction
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop
-
Nov 17, 2026, 10:30Cheng-Hock Toh: Haematology Is Everywhere – But Is It Recognised?
-
Nov 17, 2026, 10:23Akshat Jain: The Importance of Knowing Your Sickle Cell Status
-
Nov 17, 2026, 10:12Caitlin Raymond: What Does Apheresis Really Cost?